Zobrazeno 1 - 10
of 146
pro vyhledávání: '"H. Moessler"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K, Gharagozli, A A, Harandi, S, Houshmand, N, Akbari, D F, Muresanu, J, Vester, S, Winter, H, Moessler
Publikováno v:
Journal of Medicine and Life
Background and Purpose: The aim of this study was to evaluate the efficacy, safety, and tolerability of cerebrolysin in the early recovery phase after acute ischemic stroke. Methods. This prospective, randomized, double-blinded, placebo-controlled, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18e98e37ee46d2ec7ea008c5c06fd2b0
https://pubmed.ncbi.nlm.nih.gov/29075343
https://pubmed.ncbi.nlm.nih.gov/29075343
Autor:
C. Sampedro, E. Granizo, Ramón Cacabelos, X. A. Alvarez, H. Moessler, C. Linares, E. Doppler, M. Aleixandre
Publikováno v:
European Journal of Neurology. 18:59-68
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimers disease (AD) (ITT data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9773564d1a1ba492c6e024d540fd04a0
https://doi.org/10.1111/j.1468-1331.2010.03092.x
https://doi.org/10.1111/j.1468-1331.2010.03092.x
Publikováno v:
International Journal of Stroke. 4:406-412
Cerebrolysin has exhibited neuroprotective as well as neurotrophic properties in various animal models of cerebral ischaemia and has shown clinical efficacy and good safety in several small controlled clinical studies in ischaemic stroke. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654e2d48a9013ffb08b57ea58a488660
https://doi.org/10.1111/j.1747-4949.2009.00340.x
https://doi.org/10.1111/j.1747-4949.2009.00340.x
Autor:
T. M. Ross, H. Moessler, S. Zimmermann-Meinzingen, X. F. Liu, E. Doppler, W. H. Frey, L. R. Hanson
Publikováno v:
American Journal of Neuroprotection and Neuroregeneration. 1:60-66
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46f63f35b8aa11d761e2b16ff2bf837a
https://doi.org/10.1166/ajnn.2009.1010
https://doi.org/10.1166/ajnn.2009.1010
Publikováno v:
Journal of Neural Transmission. 112:415-428
Background and purpose. Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a035c897f189210d48270c01902e3de0
https://doi.org/10.1007/s00702-004-0248-2
https://doi.org/10.1007/s00702-004-0248-2
Publikováno v:
Journal of Neural Transmission. 109:1089-1104
Cerebrolysin (Cere) is a compound with neurotrophic activity. It has been shown to be effective in the treatment of Alzheimer's disease (AD) in earlier trials. In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92f54b94017bdfaf4ddf5089e207136
https://doi.org/10.1007/s007020200092
https://doi.org/10.1007/s007020200092
Publikováno v:
Development. 122:2415-2425
The transcriptional signals underlying smooth muscle differentiation are currently unknown. We report here the complete sequence and characterization of the single mouse gene for the smooth muscle-specific protein SM 22 and the transcriptional activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b573778b59b3968b8ba0c063228776
https://doi.org/10.1242/dev.122.8.2415
https://doi.org/10.1242/dev.122.8.2415
Autor:
N A, Shamalov, L V, Stakhovskaia, D V, Burenchev, I V, Kichuk, T V, Tvorogova, A Iu, Botsina, A S, Smychkov, O B, Kerbikov, H, Moessler, P, Novak, V I, Skvortsova
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 110(12 Pt 2)
The purpose of this randomized, double-blind, placebo-controlled study was to assess safety and efficacy of cerebrolysin used in dosage 50 ml in acute ischemic stroke. Forty-seven patients with ischemic stroke, aged 45-85 years, who were admitted to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0b0ab78d90b9c466c592effb65ef11f5
https://pubmed.ncbi.nlm.nih.gov/21626816
https://pubmed.ncbi.nlm.nih.gov/21626816
Publikováno v:
Journal of Medicine and Life
The purpose of the study was to investigate the efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. The primary objective of this trial was to assess the clinical efficacy and safety of a 10–days course of therapy with a daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::971209a218d8e27de8a8d1046ef0a243
https://pubmed.ncbi.nlm.nih.gov/20968198
https://pubmed.ncbi.nlm.nih.gov/20968198